Curcumin inhibits colorectal cancer progression by regulating MDH2-mediated glycolysis and NAD+ metabolism
- 26 March 2026
- journal article
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 213, 116074
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled StudyPhytotherapy Research, 2025
- Characterization of novel mouse esophageal squamous cell carcinoma cell lines and their utility as preclinical modelsCancer Letters, 2025
- Association between individual Warburg‐related proteins and prognosis in colorectal cancerThe Journal of Pathology: Clinical Research, 2025
- Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2Cell Metabolism, 2024
- Curcumin suppresses the malignant phenotype of laryngeal squamous cell carcinoma through downregulating E2F1 to inhibit FLNANaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancerActa Pharmaceutica Sinica B, 2023
- Curcumin in cancer therapy: Exploring molecular mechanisms and overcoming clinical challengesCancer Letters, 2023
- Curcumin inhibits human cancer cell growth and migration through downregulation of SVCT2Cell Biochemistry and Function, 2023
- Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activityBiochemical Pharmacology, 2023
- Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 2Cancer Communications, 2023